Exousia Bio, Inc. (LMMY): M&A transaction — LAMY acquires Exousia Ai in reverse merger; appoints Matthew Dwyer as sole officer and director

Exousia Bio, Inc.

Closed acquisition of Exousia Ai, issuing 62,223,000 shares of common stock to Exousia Ai shareholders.
Zhang Shengwu resigned as sole officer/director; Matthew Dwyer appointed as replacement effective November 17, 2025.
Exousia Ai is a clinical-stage biotech developing plant-based exosome therapies, initially for oncology.
Exousia Ai received FDA Orphan Drug Designation in November 2025 for its exosome-based glioblastoma multiforme (GBM) treatment.
The Company adopts Exousia Ai's business plan and expects to use its proprietary exosome loading technology.

item 1.01 item 5.01 item 2.01 item 3.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Exousia Bio, Inc. completed an acquisition involving Exousia Ai, Inc. for 62,223,000 shares of Company common stock (closed 2025-11-17).

Action: acquisition
Counterparty: Exousia Ai, Inc.
Consideration: 62,223,000 shares of Company common stock
Closing: 2025-11-17

Exact text from the filing

of the issued and outstanding capital stock of Exousia Ai, with Exousia Ai becoming the Company’s wholly-owned subsidiary, in consideration of the Company’s issuing a total of 62,223,000 shares of Company common stock (the “Acquisition Shares” ) to the shareholders of Exousia Ai. On November 17, 2025, the parties closed the Reorganization Agreement, such that

View on SEC.gov

Browse all m&a transactions →

Exousia Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-25-008486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.